Eton Pharma's ET-900 program tests mecasermin injection for refractory infantile spasms, with first patient dosing planned for Q1 2027.

78% of moderate aortic stenosis patients have high-risk features that double mortality and heart failure hospitalization risk within two years, study shows.

PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...

Regulatory gaps and organizational challenges slow AI adoption in clinical trials despite proven 90% reductions in data ...

Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...

CluePoints positions RBQM architecture as the structural foundation for clinical monitoring, consolidating evidence across ...

The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...

Novartis's pelacarsen hit its Lp(a) target in 8,323 patients but missed the cardiovascular endpoint entirely, exposing a $6B ...

ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...

PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...

Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected ...

Cecolin 9 shows six-month immunogenicity data in single-dose HPV trial against Gardasil 9, with final results expected in ...